| Diagnosis and management of childhood obstructive sleep apnea syndrome CL Marcus, LJ Brooks, SD Ward, KA Draper, D Gozal, AC Halbower, ... Pediatrics 130 (3), e714-e755, 2012 | 3684* | 2012 |
| Lumacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR CE Wainwright, JS Elborn, BW Ramsey, G Marigowda, X Huang, M Cipolli, ... New England Journal of Medicine 373 (3), 220-231, 2015 | 1504 | 2015 |
| Diagnosis of cystic fibrosis: consensus guidelines from the cystic fibrosis foundation PM Farrell, TB White, CL Ren, SE Hempstead, F Accurso, N Derichs, ... The Journal of pediatrics 181, S4-S15. e1, 2017 | 938 | 2017 |
| Inability of clinical history to distinguish primary snoring from obstructive sleep apnea syndrome in children JL Carroll, SA McColley, CL Marcus, S Curtis, GM Loughlin Chest 108 (3), 610-618, 1995 | 813 | 1995 |
| Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health PA Flume, BP O'Sullivan, KA Robinson, CH Goss, PJ Mogayzel Jr, ... American journal of respiratory and critical care medicine 176 (10), 957-969, 2007 | 803 | 2007 |
| Clinical significance of microbial infection and adaptation in cystic fibrosis AR Hauser, M Jain, M Bar-Meir, SA McColley Clinical microbiology reviews 24 (1), 29-70, 2011 | 524 | 2011 |
| A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised … MP Boyle, SC Bell, MW Konstan, SA McColley, SM Rowe, E Rietschel, ... The lancet Respiratory medicine 2 (7), 527-538, 2014 | 520 | 2014 |
| Respiratory compromise after adenotonsillectomy in children with obstructive sleep apnea SA McColley, MM April, JL Carroll, RM Naclerio, GM Loughlin Archives of Otolaryngology–Head & Neck Surgery 118 (9), 940-943, 1992 | 408 | 1992 |
| Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial E Kerem, MW Konstan, K De Boeck, FJ Accurso, I Sermet-Gaudelus, ... The Lancet Respiratory Medicine 2 (7), 539-547, 2014 | 375 | 2014 |
| Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax PA Flume, PJ Mogayzel Jr, KA Robinson, RL Rosenblatt, L Quittell, ... American journal of respiratory and critical care medicine 182 (3), 298-306, 2010 | 323 | 2010 |
| Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial F Ratjen, C Hug, G Marigowda, S Tian, X Huang, S Stanojevic, CE Milla, ... The lancet Respiratory medicine 5 (7), 557-567, 2017 | 318 | 2017 |
| Upper airway collapsibility in children with obstructive sleep apnea syndrome CL Marcus, SA McColley, JL Carroll, GM Loughlin, PL Smith, ... Journal of applied physiology 77 (2), 918-924, 1994 | 312 | 1994 |
| High prevalence of allergic sensitization in children with habitual snoring and obstructive sleep apnea SA McColley, JL Carroll, S Curtis, GM Loughlin, HA Sampson Chest 111 (1), 170-173, 1997 | 264 | 1997 |
| Ivacaftor treatment of cystic fibrosis in children aged 12 to< 24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study M Rosenfeld, CE Wainwright, M Higgins, LT Wang, C McKee, D Campbell, ... The lancet respiratory medicine 6 (7), 545-553, 2018 | 233 | 2018 |
| Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial RB Moss, PA Flume, JS Elborn, J Cooke, SM Rowe, SA McColley, ... The Lancet Respiratory Medicine 3 (7), 524-533, 2015 | 221 | 2015 |
| Airway microbiota across age and disease spectrum in cystic fibrosis ET Zemanick, BD Wagner, CE Robertson, RC Ahrens, JF Chmiel, ... European Respiratory Journal 50 (5), 2017 | 215 | 2017 |
| Type III Secretion Phenotypes of Pseudomonas aeruginosa Strains Change during Infection of Individuals with Cystic Fibrosis M Jain, D Ramirez, R Seshadri, JF Cullina, CA Powers, GS Schulert, ... Journal of Clinical Microbiology 42 (11), 5229-5237, 2004 | 206 | 2004 |
| A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele ET Zemanick, JL Taylor-Cousar, J Davies, RL Gibson, MA Mall, ... American journal of respiratory and critical care medicine 203 (12), 1522-1532, 2021 | 179 | 2021 |
| Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection BC Trapnell, SA McColley, DG Kissner, MW Rolfe, JM Rosen, M McKevitt, ... American journal of respiratory and critical care medicine 185 (2), 171-178, 2012 | 147 | 2012 |
| Lung function decline from adolescence to young adulthood in cystic fibrosis SL VandenBranden, A McMullen, MS Schechter, DJ Pasta, RL Michaelis, ... Pediatric pulmonology 47 (2), 135-143, 2012 | 143 | 2012 |
Michael KonstanCase Western Reserve University School of MedicineVerified email at case.edu
